Eli Lilly and Company (LILY34) — Cash Flow-to-Debt Ratio
Eli Lilly and Company (LILY34) has a Cash Flow-to-Debt Ratio of 0.04x as of December 2025, meaning its operating cash flow of R$3.22 Billion could theoretically repay 0% of its total liabilities (R$85.94 Billion) in one year. See Eli Lilly and Company free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eli Lilly and Company Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Eli Lilly and Company across 12 annual periods. Also explore Eli Lilly and Company (LILY34) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Eli Lilly and Company (2014–2025)
Year-by-year debt coverage analysis for Eli Lilly and Company. For market capitalisation and broader financial context, see market value of Eli Lilly and Company.
| Year | CF-to-Debt Ratio | Operating CF (BRL) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.20x | R$16.81 Billion | R$85.94 Billion | ▲ +43.0% |
| 2024 | 0.14x | R$8.82 Billion | R$64.44 Billion | ▲ +27.3% |
| 2023 | 0.11x | R$5.71 Billion | R$53.14 Billion | ▼ -41.1% |
| 2022 | 0.18x | R$7.08 Billion | R$38.84 Billion | ▼ -0.4% |
| 2021 | 0.18x | R$7.26 Billion | R$39.65 Billion | ▲ +15.5% |
| 2020 | 0.16x | R$6.50 Billion | R$40.99 Billion | ▲ +20.2% |
| 2019 | 0.13x | R$4.84 Billion | R$36.68 Billion | ▼ -18.7% |
| 2018 | 0.16x | R$5.52 Billion | R$34.08 Billion | ▼ -3.6% |
| 2017 | 0.17x | R$5.62 Billion | R$33.39 Billion | ▼ -14.0% |
| 2016 | 0.20x | R$4.85 Billion | R$24.80 Billion | ▲ +38.4% |
| 2015 | 0.14x | R$2.96 Billion | R$20.98 Billion | ▼ -33.7% |
| 2014 | 0.21x | R$4.46 Billion | R$20.92 Billion | — |